Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model

J. L. Lukkes, H. P. Drozd, S. D. Fitz, A. I. Molosh, D. W. Clapp, A. Shekhar

Research output: Contribution to journalArticle

Abstract

Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with a mutation in one copy of the neurofibromin gene (NF1 +/- ). Even though approximately 40-60% of children with NF1 meet the criteria for attention deficit hyperactivity disorder (ADHD), very few preclinical studies, if any, have investigated alterations in impulsivity and risk-taking behavior. Mice with deletion of a single NF1 gene (Nf1 +/- ) recapitulate many of the phenotypes of NF1 patients. Methods: We compared wild-type (WT) and Nf1 +/- mouse strains to investigate differences in impulsivity and hyperactivity using the delay discounting task (DDT), cliff avoidance reaction (CAR) test, and open field. We also investigated whether treatment with the clinically effective alpha-2A adrenergic receptor agonist, guanfacine (0.3 mg/kg, i.p.), would reverse deficits observed in behavioral inhibition. Results: Nf1 +/- mice chose a higher percentage of smaller rewards when both 10- A nd 20-s delays were administered compared to WT mice, suggesting Nf1 +/- mice are more impulsive. When treated with guanfacine (0.3 mg/kg, i.p.), Nf1 +/- mice exhibited decreased impulsive choice by waiting for the larger, delayed reward. Nf1 +/- mice also exhibited deficits in behavioral inhibition compared to WT mice in the CAR test by repetitively entering the outer edge of the platform where they risk falling. Treatment with guanfacine ameliorated these deficits. In addition, Nf1 +/- mice exhibited hyperactivity as increased distance was traveled compared to WT controls in the open field. This hyperactivity in Nf1 +/- mice was reduced with guanfacine pre-treatment. Conclusions: Overall, our study confirms that Nf1 +/- mice exhibit deficits in behavioral inhibition in multiple contexts, a key feature of ADHD, and can be used as a model system to identify alterations in neural circuitry associated with symptoms of ADHD in children with NF1.

Original languageEnglish (US)
Article number2
JournalJournal of Neurodevelopmental Disorders
Volume12
Issue number1
DOIs
StatePublished - Jan 15 2020

Fingerprint

Guanfacine
Neurofibromatosis 1
Impulsive Behavior
Attention Deficit Disorder with Hyperactivity
Phenotype
Therapeutics
Reward
Accidental Falls
Neurofibromatosis 1 Genes
Neurofibromin 1
Adrenergic alpha-2 Receptors
Adrenergic alpha-Agonists
Risk-Taking

Keywords

  • ADHD
  • Alpha 2A-adrenergic receptor agonist
  • Behavioral inhibition
  • Cliff avoidance reaction test
  • Delay discounting
  • Guanfacine
  • Hyperactivity
  • Impulsivity
  • Mouse
  • Neurofibromatosis type 1

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model. / Lukkes, J. L.; Drozd, H. P.; Fitz, S. D.; Molosh, A. I.; Clapp, D. W.; Shekhar, A.

In: Journal of Neurodevelopmental Disorders, Vol. 12, No. 1, 2, 15.01.2020.

Research output: Contribution to journalArticle

@article{afede201bd0b4914888758458f7fe518,
title = "Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model",
abstract = "Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with a mutation in one copy of the neurofibromin gene (NF1 +/- ). Even though approximately 40-60{\%} of children with NF1 meet the criteria for attention deficit hyperactivity disorder (ADHD), very few preclinical studies, if any, have investigated alterations in impulsivity and risk-taking behavior. Mice with deletion of a single NF1 gene (Nf1 +/- ) recapitulate many of the phenotypes of NF1 patients. Methods: We compared wild-type (WT) and Nf1 +/- mouse strains to investigate differences in impulsivity and hyperactivity using the delay discounting task (DDT), cliff avoidance reaction (CAR) test, and open field. We also investigated whether treatment with the clinically effective alpha-2A adrenergic receptor agonist, guanfacine (0.3 mg/kg, i.p.), would reverse deficits observed in behavioral inhibition. Results: Nf1 +/- mice chose a higher percentage of smaller rewards when both 10- A nd 20-s delays were administered compared to WT mice, suggesting Nf1 +/- mice are more impulsive. When treated with guanfacine (0.3 mg/kg, i.p.), Nf1 +/- mice exhibited decreased impulsive choice by waiting for the larger, delayed reward. Nf1 +/- mice also exhibited deficits in behavioral inhibition compared to WT mice in the CAR test by repetitively entering the outer edge of the platform where they risk falling. Treatment with guanfacine ameliorated these deficits. In addition, Nf1 +/- mice exhibited hyperactivity as increased distance was traveled compared to WT controls in the open field. This hyperactivity in Nf1 +/- mice was reduced with guanfacine pre-treatment. Conclusions: Overall, our study confirms that Nf1 +/- mice exhibit deficits in behavioral inhibition in multiple contexts, a key feature of ADHD, and can be used as a model system to identify alterations in neural circuitry associated with symptoms of ADHD in children with NF1.",
keywords = "ADHD, Alpha 2A-adrenergic receptor agonist, Behavioral inhibition, Cliff avoidance reaction test, Delay discounting, Guanfacine, Hyperactivity, Impulsivity, Mouse, Neurofibromatosis type 1",
author = "Lukkes, {J. L.} and Drozd, {H. P.} and Fitz, {S. D.} and Molosh, {A. I.} and Clapp, {D. W.} and A. Shekhar",
year = "2020",
month = "1",
day = "15",
doi = "10.1186/s11689-019-9304-y",
language = "English (US)",
volume = "12",
journal = "Journal of Neurodevelopmental Disorders",
issn = "1866-1947",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model

AU - Lukkes, J. L.

AU - Drozd, H. P.

AU - Fitz, S. D.

AU - Molosh, A. I.

AU - Clapp, D. W.

AU - Shekhar, A.

PY - 2020/1/15

Y1 - 2020/1/15

N2 - Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with a mutation in one copy of the neurofibromin gene (NF1 +/- ). Even though approximately 40-60% of children with NF1 meet the criteria for attention deficit hyperactivity disorder (ADHD), very few preclinical studies, if any, have investigated alterations in impulsivity and risk-taking behavior. Mice with deletion of a single NF1 gene (Nf1 +/- ) recapitulate many of the phenotypes of NF1 patients. Methods: We compared wild-type (WT) and Nf1 +/- mouse strains to investigate differences in impulsivity and hyperactivity using the delay discounting task (DDT), cliff avoidance reaction (CAR) test, and open field. We also investigated whether treatment with the clinically effective alpha-2A adrenergic receptor agonist, guanfacine (0.3 mg/kg, i.p.), would reverse deficits observed in behavioral inhibition. Results: Nf1 +/- mice chose a higher percentage of smaller rewards when both 10- A nd 20-s delays were administered compared to WT mice, suggesting Nf1 +/- mice are more impulsive. When treated with guanfacine (0.3 mg/kg, i.p.), Nf1 +/- mice exhibited decreased impulsive choice by waiting for the larger, delayed reward. Nf1 +/- mice also exhibited deficits in behavioral inhibition compared to WT mice in the CAR test by repetitively entering the outer edge of the platform where they risk falling. Treatment with guanfacine ameliorated these deficits. In addition, Nf1 +/- mice exhibited hyperactivity as increased distance was traveled compared to WT controls in the open field. This hyperactivity in Nf1 +/- mice was reduced with guanfacine pre-treatment. Conclusions: Overall, our study confirms that Nf1 +/- mice exhibit deficits in behavioral inhibition in multiple contexts, a key feature of ADHD, and can be used as a model system to identify alterations in neural circuitry associated with symptoms of ADHD in children with NF1.

AB - Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with a mutation in one copy of the neurofibromin gene (NF1 +/- ). Even though approximately 40-60% of children with NF1 meet the criteria for attention deficit hyperactivity disorder (ADHD), very few preclinical studies, if any, have investigated alterations in impulsivity and risk-taking behavior. Mice with deletion of a single NF1 gene (Nf1 +/- ) recapitulate many of the phenotypes of NF1 patients. Methods: We compared wild-type (WT) and Nf1 +/- mouse strains to investigate differences in impulsivity and hyperactivity using the delay discounting task (DDT), cliff avoidance reaction (CAR) test, and open field. We also investigated whether treatment with the clinically effective alpha-2A adrenergic receptor agonist, guanfacine (0.3 mg/kg, i.p.), would reverse deficits observed in behavioral inhibition. Results: Nf1 +/- mice chose a higher percentage of smaller rewards when both 10- A nd 20-s delays were administered compared to WT mice, suggesting Nf1 +/- mice are more impulsive. When treated with guanfacine (0.3 mg/kg, i.p.), Nf1 +/- mice exhibited decreased impulsive choice by waiting for the larger, delayed reward. Nf1 +/- mice also exhibited deficits in behavioral inhibition compared to WT mice in the CAR test by repetitively entering the outer edge of the platform where they risk falling. Treatment with guanfacine ameliorated these deficits. In addition, Nf1 +/- mice exhibited hyperactivity as increased distance was traveled compared to WT controls in the open field. This hyperactivity in Nf1 +/- mice was reduced with guanfacine pre-treatment. Conclusions: Overall, our study confirms that Nf1 +/- mice exhibit deficits in behavioral inhibition in multiple contexts, a key feature of ADHD, and can be used as a model system to identify alterations in neural circuitry associated with symptoms of ADHD in children with NF1.

KW - ADHD

KW - Alpha 2A-adrenergic receptor agonist

KW - Behavioral inhibition

KW - Cliff avoidance reaction test

KW - Delay discounting

KW - Guanfacine

KW - Hyperactivity

KW - Impulsivity

KW - Mouse

KW - Neurofibromatosis type 1

UR - http://www.scopus.com/inward/record.url?scp=85077940881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077940881&partnerID=8YFLogxK

U2 - 10.1186/s11689-019-9304-y

DO - 10.1186/s11689-019-9304-y

M3 - Article

C2 - 31941438

AN - SCOPUS:85077940881

VL - 12

JO - Journal of Neurodevelopmental Disorders

JF - Journal of Neurodevelopmental Disorders

SN - 1866-1947

IS - 1

M1 - 2

ER -